Literature DB >> 25414153

Association between hemoglobin A1c and all-cause mortality: results of the mortality follow-up of the German National Health Interview and Examination Survey 1998.

Rebecca Paprott1, Angelika Schaffrath Rosario1, Markus A Busch1, Yong Du1, Silke Thiele2, Christa Scheidt-Nave1, Christin Heidemann3.   

Abstract

OBJECTIVE: This study examined the association of HbA1c-defined glycemic status and continuous HbA1c with all-cause mortality. RESEARCH DESIGN AND METHODS: The study population comprised 6,299 participants (aged 18-79 years) of the German National Health Interview and Examination Survey 1998, who were followed up for mortality for an average of 11.6 years. Glycemic status was defined as known diabetes (self-reported diagnosis or intake of antidiabetic medication) and based on HbA1c levels according to American Diabetes Association diagnostic criteria as undiagnosed diabetes (≥6.5% [≥48 mmol/mol]), prediabetes with very high (6.0-6.4% [42-46 mmol/mol]) or high diabetes risk (5.7-5.9% [39-41 mmol/mol]), and normoglycemia (<5.7% [<39 mmol/mol]). Associations between glycemic status and mortality were examined by Cox regression adjusting for age, sex, education, lifestyle factors, anthropometric measures, and history of chronic diseases (reference: normoglycemia). Spline models were fitted to investigate associations between continuous HbA1c and mortality among participants without known diabetes.
RESULTS: Excess mortality risk was observed for participants with known diabetes (hazard ratio 1.41 [95% CI 1.08-1.84]) and undiagnosed diabetes (1.63 [1.23-2.17]) but not for those with high (1.02 [0.80-1.30]) or very high diabetes risk (0.87 [0.67-1.13]). Spline models revealed a U-shaped association, with lowest risk at HbA1c levels 5.4-5.6% (36-38 mmol/mol) and a significantly increased risk at ≤5.0% (≤31 mmol/mol) and ≥6.4% (≥46 mmol/mol).
CONCLUSIONS: Unlike known and undiagnosed diabetes, HbA1c levels in the prediabetic range were not associated with an increased mortality risk. The observed U-shaped relationship adds to existing evidence that not only high but also low HbA1c levels might be associated with all-cause mortality.
© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25414153     DOI: 10.2337/dc14-1787

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  21 in total

1.  Hyperglycemia, Classified with Multiple Biomarkers Simultaneously in Men without Diabetes, and Risk of Fatal Prostate Cancer.

Authors:  Michael T Marrone; Elizabeth Selvin; John R Barber; Elizabeth A Platz; Corinne E Joshu
Journal:  Cancer Prev Res (Phila)       Date:  2018-12-11

2.  Glycated Hemoglobin and All-Cause and Cause-Specific Mortality Among Adults With and Without Diabetes.

Authors:  Fu-Rong Li; Xi-Ru Zhang; Wen-Fang Zhong; Zhi-Hao Li; Xiang Gao; Virginia Byers Kraus; Yue-Bin Lv; Meng-Chen Zou; Guo-Chong Chen; Pei-Liang Chen; Min-Yi Zhang; Akech Kuol Akech Kur; Xiao-Ming Shi; Xian-Bo Wu; Chen Mao
Journal:  J Clin Endocrinol Metab       Date:  2019-08-01       Impact factor: 5.958

3.  Association between visit-to-visit variability of glycemic indices and lipid profile and the incidence of coronary heart disease in adults with type 2 diabetes.

Authors:  Fatemeh Moosaie; Marjan Mouodi; Ali Sheikhy; Aida Fallahzadeh; Niloofar Deravi; Soghra Rabizadeh; Seyede Marzie Fatemi Abhari; Alipasha Meysamie; Fatemeh Dehghani Firouzabadi; Manouchehr Nakhjavani; Alireza Esteghamati
Journal:  J Diabetes Metab Disord       Date:  2021-11-02

4.  Association between haemoglobin A1c and all-cause and cause-specific mortality in middle-aged and older Koreans: a prospective cohort study.

Authors:  Bo Mi Song; Jung Hyun Lee; Hae Dong Woo; Mi Jin Cho; Sung Soo Kim
Journal:  Nutr Metab (Lond)       Date:  2022-07-14       Impact factor: 4.654

5.  Low HbA1c levels and all-cause or cardiovascular mortality among people without diabetes: the US National Health and Nutrition Examination Survey 1999-2015.

Authors:  Kosuke Inoue; Roch Nianogo; Donatello Telesca; Atsushi Goto; Vahe Khachadourian; Yusuke Tsugawa; Takehiro Sugiyama; Elizabeth Rose Mayeda; Beate Ritz
Journal:  Int J Epidemiol       Date:  2021-08-30       Impact factor: 7.196

6.  Association of 1,5-Anhydroglucitol With Cardiovascular Disease and Mortality.

Authors:  Elizabeth Selvin; Andreea Rawlings; Pamela Lutsey; Nisa Maruthur; James S Pankow; Michael Steffes; Josef Coresh
Journal:  Diabetes       Date:  2015-09-22       Impact factor: 9.461

7.  HbA1c levels in non-diabetic older adults - No J-shaped associations with primary cardiovascular events, cardiovascular and all-cause mortality after adjustment for confounders in a meta-analysis of individual participant data from six cohort studies.

Authors:  Ben Schöttker; W Rathmann; C Herder; B Thorand; T Wilsgaard; I Njølstad; G Siganos; E B Mathiesen; K U Saum; A Peasey; E Feskens; P Boffetta; A Trichopoulou; K Kuulasmaa; F Kee; H Brenner
Journal:  BMC Med       Date:  2016-02-11       Impact factor: 8.775

Review 8.  Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis.

Authors:  Yuli Huang; Xiaoyan Cai; Weiyi Mai; Meijun Li; Yunzhao Hu
Journal:  BMJ       Date:  2016-11-23

9.  HbA1c and Risks of All-Cause and Cause-Specific Death in Subjects without Known Diabetes: A Dose-Response Meta-Analysis of Prospective Cohort Studies.

Authors:  Guo-Chao Zhong; Ming-Xin Ye; Jia-Hao Cheng; Yong Zhao; Jian-Ping Gong
Journal:  Sci Rep       Date:  2016-04-05       Impact factor: 4.379

10.  Relationship between glycated hemoglobin, Intensive Care Unit admission blood sugar and glucose control with ICU mortality in critically ill patients.

Authors:  Ata Mahmoodpoor; Hadi Hamishehkar; Kamran Shadvar; Mohammadtaghi Beigmohammadi; Afshin Iranpour; Sarvin Sanaie
Journal:  Indian J Crit Care Med       Date:  2016-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.